Merck
CN
  • The impact of early intra-articular administration of interleukin-1 receptor antagonist on lubricin metabolism and cartilage degeneration in an anterior cruciate ligament transection model.

The impact of early intra-articular administration of interleukin-1 receptor antagonist on lubricin metabolism and cartilage degeneration in an anterior cruciate ligament transection model.

Osteoarthritis and cartilage (2014-09-16)
K A Elsaid, L Zhang, Z Shaman, C Patel, T A Schmidt, G D Jay
摘要

Study the impact of intra-articular interleukin-1 receptor antagonist (IL-1 ra) treatment on lubricin biosynthesis following anterior cruciate ligament transection (ACLT) in the rat and evaluate the effect of combined IL-1 ra and recombinant human lubricin (rhPRG4) treatments on chondrocyte apoptosis. ACLT was performed in male Lewis rats. Treatments included IL-1 ra or vehicle (n = 36 in each group). IL-1 ra intra-articular dosing was performed on days 1, 3, 5 and 7 following ACLT using Anakinra (150 mg/ml; 40 μl). At 3 and 5 weeks, animals were sacrificed and RNA was isolated. Histological analyses included Safranin O and H&E. Lubricin synovial fluid (SF) lavage concentrations were determined at 5 weeks. ACLT animals were treated with a single injection of vehicle, IL-1 ra (75 mg/ml; 40 μl), rhPRG4 (200 μg/ml; 40 μl), or IL-1 ra + rhPRG4 (75 mg/ml + 200 μg/ml; 40 μl) (n = 6 in each group) on day 7 following ACLT and cartilage was probed for cleaved caspase-3 at 5 weeks. IL-1 ra treatment improved lubricin expression (P < 0.001) and lubricin SF lavage concentrations in the IL-1 ra group was higher (P = 0.005) than the vehicle. IL-1 ra treatment reduced cartilage and synovial scores (P < 0.001) compared to vehicle. IL-1 ra and rhPRG4 acted synergistically to reduce caspase-3 positive chondrocytes (P < 0.001) compared to individual treatments. IL-1 ra treatment preserved lubricin following ACLT and a combined treatment of IL-1 ra + rhPRG4 may act synergistically to reduce cartilage catabolism.

材料
货号
品牌
产品描述

Sigma-Aldrich
尿素, ACS reagent, 99.0-100.5%
Sigma-Aldrich
尿素, powder, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
L-谷氨酰胺, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
尿素, ReagentPlus®, ≥99.5%, pellets
Sigma-Aldrich
胸苷, powder, BioReagent, suitable for cell culture
Supelco
尿素, 8 M (after reconstitution with 16 mL high purity water)
Sigma-Aldrich
尿素 溶液, BioUltra, ~8 M in H2O
Sigma-Aldrich
L-谷氨酰胺, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
肌酸酐, anhydrous, ≥98%
Sigma-Aldrich
尿素, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%, 99.0-101.0% (calc. on dry substance)
Sigma-Aldrich
胸苷, ≥99%
Sigma-Aldrich
次黄嘌呤, ≥99.0%
SAFC
L-谷氨酰胺
Sigma-Aldrich
次黄嘌呤, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
尿素, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99%
Sigma-Aldrich
尿素, BioXtra, pH 7.5-9.5 (20 °C, 5 M in H2O)
Sigma-Aldrich
尿素, suitable for electrophoresis
Sigma-Aldrich
尿素, BioUltra, for molecular biology, 99% (T)
Sigma-Aldrich
L-谷氨酰胺, BioUltra, ≥99.5% (NT)
USP
尿素, United States Pharmacopeia (USP) Reference Standard
Supelco
肌酐, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-谷氨酰胺, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
尿素 溶液, 40 % (w/v) in H2O
Sigma-Aldrich
尿素, meets USP testing specifications
Sigma-Aldrich
胸苷, ≥99.0% (HPLC)
Supelco
尿素, analytical standard
Sigma-Aldrich
L-谷氨酰胺, γ-irradiated, BioXtra, suitable for cell culture
Millipore
尿素 溶液, suitable for microbiology, 40% in H2O
Sigma-Aldrich
L-谷氨酰胺
Supelco
L-谷氨酰胺, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland